cytochalasin-e has been researched along with Leukemia--Myeloid--Acute* in 1 studies
1 other study(ies) available for cytochalasin-e and Leukemia--Myeloid--Acute
Article | Year |
---|---|
Mechanism of action of phorbol myristate acetate on human natural killer cell activity.
We have investigated the kinetics of inhibition and regeneration of human natural killer (NK) cell-mediated lysis of K562, a human erythroleukemia cell line, by the potent tumor-promoting agent phorbol-12-myristate-13-acetate (PMA). It is shown that PMA inhibits NK cell-mediated cytotoxicity (CMC) in a dose-dependent manner whether the compound is present throughout the 4-hr cytotoxic assay or the effector cells (EC) are pretreated with PMA. Pretreatment of the target cells (TC) with PMA produced a different profile of NK activity suggesting that PMA inhibition of NK-CMC is primarily due to the inactivation of EC. PMA-induced inhibition of NK-CMC does not affect TC binding and is not circumvented by compounds that enhance intracellular levels of cyclic guanosine monophosphate (cGMP) or calcium. Furthermore, and contrary to a recent report, PMA-induced inhibition of NK-CMC is independent of monocytes. Finally, kinetic studies revealed that PMA-induced inhibition of NK-CMC occurs rapidly and is fully reversible provided that "regenerated EC" are thoroughly washed, prior to the cytotoxic assay, to rid the cell suspension of residual PMA. The potential implications of these results to the currently accepted theory of TC destruction by NK cells, the stimulus-secretion model, are discussed. Topics: Calcimycin; Cell Adhesion; Cell Line; Cytochalasins; Cytotoxicity, Immunologic; Humans; Killer Cells, Natural; Kinetics; Leukemia, Myeloid, Acute; Mycotoxins; Phorbols; Tetradecanoylphorbol Acetate | 1983 |